Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 18, 2016. The document serves as a transaction notification regarding a Person Discharging Managerial Responsibilities (PDMR) or a person closely associated with them, rather than a periodic financial report.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific share transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of Ordinary Shares |
| Instrument | Ordinary shares of 25 pence each (ISIN: GB0009252882) |
| Transaction Price | £16.6373 |
| Volume | 4 shares |
| Date of Transaction | July 14, 2016 |
| Exchange | London Stock Exchange (XLON) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records a routine acquisition of shares by Mr. N Hirons (SVP, Global Ethics & Compliance) following the re-investment of dividends paid on July 14, 2016, under the Company's ShareReward Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. It is a regulatory disclosure of a specific insider transaction.
Key Facts for Investor Verification
- The transaction involved the acquisition of 4 ordinary shares by a senior executive.
- The purchase was executed via dividend re-investment under the ShareReward Plan.
- The transaction price was £16.6373 per share on the London Stock Exchange.
- This filing does not contain quarterly or annual financial results.